Nucala 100 mg Lyophilisat zur Herstellung einer Injektionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

nucala 100 mg lyophilisat zur herstellung einer injektionslösung

glaxosmithkline ag - mepolizumabum - lyophilisat zur herstellung einer injektionslösung - praeparatio cryodesiccata: mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus corresp. natrium 1.5-2 mg, polysorbatum 80, acidum hydrochloricum q.s. ad ph pro vitro. - zusatztherapie bei schwerem eosinophilem asthma, zusatztherapie bei erwachsenen mit egpa - biotechnologika

Nucala 100 mg/mL Injektionslösung im Fertigpen Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

nucala 100 mg/ml injektionslösung im fertigpen

glaxosmithkline ag - mepolizumabum - injektionslösung im fertigpen - mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus, acidum citricum monohydricum, polysorbatum 80 dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.0 ml. - eosinophiles asthma, egpa, crswnp, hes - biotechnologika

Nucala 100 mg/mL Injektionslösung in der Fertigspritze Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

nucala 100 mg/ml injektionslösung in der fertigspritze

glaxosmithkline ag - mepolizumabum - injektionslösung in der fertigspritze - mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus, acidum citricum monohydricum, polysorbatum 80 dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.0 ml. - eosinophiles asthma, egpa, crswnp, hes - biotechnologika

Nucala Europäische Union - Deutsch - EMA (European Medicines Agency)

nucala

glaxosmithkline trading services - mepolizumab - asthma - medikamente für obstruktive atemwegserkrankungen, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.